In this study, we confirmed that the inhibition of the NK‐1R‐induced apoptosis in human colon cancer cells was in accordance with the findings of other research groups.[10a,c] This study was the first to demonstrate the in vivo efficacy of NK‐1R antagonist in inhibiting tumor growth and improving the efficacy of chemotherapy by overcoming chemoresistance in CRC xenograft mouse models. Here, TACR1 is linked to colorectal carcinoma.